Table S1. Baseline characteristics of participants who initiated dialysis who were included versus

excluded in the analysis.

excluded in the analysis.		lm a local a	
Variable	Exclude	Include	P voluo <sup>3</sup>
Variable Variable	(n=465) <sup>1</sup>	(n=417) <sup>2</sup> 55.56±11.00	value <sup>3</sup>
Age, year, mean±SD	57.08±12.04		0.05
Men, N(%)	281 (60.43%)	245 (58.75%)	0.6
Race, N(%)	400 (00 040/)	00 (40 000()	0.4
Non-Hispanic white	122 (26.24%)	82 (19.66%)	0.1
Non-Hispanic black	241 (51.83%)	234 (56.12%)	•
Hispanic	84 (18.06%)	85 (20.38%)	•
Other	18 (3.87%)	16 (3.84%)	
Current smoker, N(%)	87 (18.71%)	65 (15.59%)	0.2
Estimated glomerular filtration rate,	32.53±11.33	32.05±10.28	0.5
ml/min/1.73m², mean±SD	00.45.0.40	00.07.0.04	0.0
BMI, kg/m², mean±SD	32.45±8.19	33.07±8.24	0.3
Systolic blood pressure, mmHg, mean±SD	139.81±24.45	139.64±23.34	0.9
Diastolic blood pressure, mmHg, mean±SD	73.73±14.47	75.03±13.69	0.2
LDL, mg/dl, mean±SD	105.37±42.53	103.38±39.92	0.5
HDL, mg/dl, mean±SD	45.60±15.47	45.83±14.51	0.8
Triglycerides, mg/dl, median (IQR)	140.00 (99.00-	149.00 (98.50-	0.6
T. I.	208.00)	208.00)	
Total cholesterol, mg/dl, mean±SD	190.19±59.13	188.10±51.74	0.6
Hemoglobin, g/dl, mean±SD	11.87±1.79	11.79±1.82	0.5
HbA1c hemoglobin, %, mean±SD	7.30±1.94	7.08±1.75	0.08
Serum albumin, g/dl, mean±SD	3.66±0.54	3.64±0.53	0.6
Hypertension, N(%)	435 (93.55%)	402 (96.40%)	0.05
Cardiovascular disease, N(%)	199 (42.80%)	161 (38.61%)	0.2
Chronic obstructive pulmonary disease, N(%)	17 (3.73%)	11 (2.68%)	0.4
Diabetes, N(%)	312 (67.10%)	283 (67.87%)	8.0
β-blockers, N(%)	301 (65.43%)	230 (55.42%)	0.003
Angiotensin converting enzyme inhibitors or	330 (71.74%)	295 (71.08%)	8.0
angiotensin receptor blockers, N(%)			
Calcium channel blockers, N(%)	238 (51.74%)	232 (55.90%)	0.2
Diuretics, N(%)	320 (69.57%)	298 (71.81%)	0.5
Number of anti-hypertensive med classes, N(%)	3.21±1.54	3.19±1.51	0.8
Left ventricular mass index, g/m <sup>2.74</sup>	57.38±14.12	59.35±15.22	0.1
Ejection fraction, % <sup>4</sup>	52.65±8.72	52.90±8.60	0.7
Left ventricular geometry <sup>4</sup>			0.7
Normal	24 (9.56%)	29 (10.03%)	
Concentric remodeling	51 (20.32%)	48 (16.61%)	
Eccentric hypertrophy	55 (21.91%)	62 (21.45%)	
Concentric hypertrophy	121 (48.21%)	150 (51.90%)	
Diastolic relaxation <sup>4</sup>	,	,	0.4
Normal relaxation	66 (23.74%)	81 (25.96%)	
Mildly abnormal relaxation	186 (66.91%)	193 (61.86%)	
Moderately & Severely abnormal relaxation	26 (9.35%) <sup>′</sup>	38 (12.18%)	
Left atrial volume (ml/m²) 4	4.10±0.69	4.08±0.62	0.7

<sup>&</sup>lt;sup>1</sup>Participants who did not have >= 1 pre-ESRD and >= 1 post-ESRD for any echo variables are excluded.

<sup>&</sup>lt;sup>2</sup>Participants who had >= 1 pre-ESRD and >= 1 post-ESRD for any echo variables are included.

<sup>&</sup>lt;sup>3</sup>For continuous variables, the p values are generated using the Student's t test or the Wilcoxon rank sum test; for categorical variables, the p values are generated using the chi-squared test.

<sup>&</sup>lt;sup>4</sup> Baseline echocardiogram was performed at Year 1. Among 465 participants who are excluded, 372 of them had a visit at year 1. Among 417 participants who are included, 408 of them had a visit at year 1.